RhumbLine Advisers
TYRA icon

RhumbLine Advisers’s Tyra Biosciences TYRA Stock Holding History

RhumbLine Advisers’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Buy
52,039
+12,379
+31% +$410K ﹤0.01% 2043
2026
Q1 		$1.52M Buy
39,660
+870
+2% +$28.2K ﹤0.01% 2004
2025
Q4 		$1.02M Sell
38,790
-1,846
-5% -$33.9K ﹤0.01% 2214
2025
Q3 		$568K Sell
40,636
-49
-0.1% -$559 ﹤0.01% 2609
2025
Q2 		$389K Buy
40,685
+12,604
+45% +$120K ﹤0.01% 2838
2025
Q1 		$261K Buy
28,081
+1,879
+7% +$24.3K ﹤0.01% 2969
2024
Q4 		$364K Buy
26,202
+1,027
+4% +$18.6K ﹤0.01% 2872
2024
Q3 		$592K Buy
25,175
+1,603
+7% +$33.7K ﹤0.01% 2590
2024
Q2 		$377K Buy
23,572
+2,574
+12% +$44.3K ﹤0.01% 2854
2024
Q1 		$344K Sell
20,998
-334
-2% -$5.48K ﹤0.01% 2900
2023
Q4 		$295K Sell
21,332
-129
-0.6% -$1.67K ﹤0.01% 2983
2023
Q3 		$296K Buy
21,461
+176
+0.8% +$2.61K ﹤0.01% 2943
2023
Q2 		$362K Sell
21,285
-641
-3% -$9.3K ﹤0.01% 2889
2023
Q1 		$352K Buy
21,926
+1,178
+6% +$14K ﹤0.01% 2564
2022
Q4 		$158K Buy
20,748
+115
+0.6% +$813 ﹤0.01% 2841
2022
Q3 		$181K Buy
20,633
+3,348
+19% +$30.6K ﹤0.01% 2918
2022
Q2 		$124K Buy
17,285
+5,559
+47% +$44.3K ﹤0.01% 3014
2022
Q1 		$125K Buy
+11,726
New +$139K ﹤0.01% 2848

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
APMC
Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

RhumbLine Advisers's TYRA Position: Q2 2026 in Review

RhumbLine Advisers increased its Tyra Biosciences (TYRA) stake by 31% in Q2 2026, buying an estimated $410K and bringing the position to 52,039 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2043.

RhumbLine Advisers first reported a position in TYRA in Q1 2022 and has held it in 18 quarters since. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • RhumbLine Advisers held 52,039 shares of Tyra Biosciences worth $1.66M as of Q2 2026.
  • RhumbLine Advisers bought 12,379 Tyra Biosciences shares in Q2 2026, an estimated $410K.
  • Tyra Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2043 holding.
  • RhumbLine Advisers first reported a position in Tyra Biosciences in Q1 2022 and has held it in 18 quarters since.
  • 168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.